SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer - Quaterly Results

29 Jul 2026 Evaluate
The company witnessed a 8.31% growth in the revenue at Rs. 6531.70 millions for the quarter ended June 2026 as compared to Rs. 6030.50 millions during the year-ago period.Net profit stood at Rs. 2044.70  millions  compared to Rs. 1917.50 millions in the corresponding previous quarter,high by 6.63%.Operating Profit saw a handsome growth to 2924.00 millions from 2771.90 millions in the quarter ended June 2026.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 6531.70 6030.50 8.31 6531.70 6030.50 8.31 25196.50 22813.50 10.45
Other Income 448.40 671.70 -33.24 448.40 671.70 -33.24 1879.50 1722.50 9.11
PBIDT 2924.00 2771.90 5.49 2924.00 2771.90 5.49 10920.40 9124.80 19.68
Interest 14.60 32.50 -55.08 14.60 32.50 -55.08 94.80 84.10 12.72
PBDT 2909.40 2739.40 6.21 2909.40 2739.40 6.21 10334.00 10768.80 -4.04
Depreciation 142.60 144.10 -1.04 142.60 144.10 -1.04 577.30 607.90 -5.03
PBT 2766.80 2595.30 6.61 2766.80 2595.30 6.61 9756.70 10160.90 -3.98
TAX 722.10 677.80 6.54 722.10 677.80 6.54 2532.40 2484.90 1.91
Deferred Tax 12.80 3.90 228.21 12.80 3.90 228.21 -42.80 -156.10 -72.58
PAT 2044.70 1917.50 6.63 2044.70 1917.50 6.63 7224.30 7676.00 -5.88
Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00
PBIDTM(%) 44.77 45.96 -2.61 44.77 45.96 -2.61 43.34 40.00 8.36

Pfizer Share Price

4755.00 49.40 (1.05%)
29-Jul-2026 15:13 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1990.00
Dr. Reddys Labs. 1142.00
Cipla 1473.70
Lupin 2445.40
Zydus Lifesciences 1123.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: